The Independent Living Donor Advocate: A Guidance Document From the American Society of Transplantation's Living Donor Community of Practice (AST LDCOP)

被引:22
作者
Hays, R. E. [1 ]
Rudow, D. LaPointe [2 ]
Dew, M. A. [3 ,4 ,5 ]
Taler, S. J. [6 ]
Spicer, H. [7 ]
Mandelbrot, D. A. [8 ]
机构
[1] Univ Wisconsin Hosp & Clin, Transplant Clin, Madison, WI 53792 USA
[2] Mt Sinai Med Ctr, Recanati Miller Transplant Inst, New York, NY 10029 USA
[3] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA
[4] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA
[5] Univ Pittsburgh, Dept Epidemiol & Biostat, Pittsburgh, PA USA
[6] Mayo Clin, Coll Med, Div Nephrol & Hypertens, Rochester, MN USA
[7] Henrico Doctors Hosp, Richmond, VA USA
[8] Beth Israel Deaconess Med Ctr, Transplant Inst, Boston, MA 02215 USA
关键词
INFORMED-CONSENT; PRACTICE GUIDELINES; KIDNEY DONORS; DONATION; STATEMENT; EDUCATE; RISK;
D O I
10.1111/ajt.13001
中图分类号
R61 [外科手术学];
学科分类号
摘要
The independent living donor advocate (ILDA) serves a mandated and supportive role in the care of the living organ donor, yet qualifications and role requirements are not clearly defined. Guidance comes from Centers for Medicare and Medicaid Services (CMS) Conditions for Transplant Center Participation and interpretive guidelines, Organ Procurement and Transplantation Network (OPTN) Policy and CMS and OPTN site surveys, yet interpretation of regulations varies. Herein, the AST Living Donor Community of Practice (LDCOP) offers seven recommendations to clarify and optimize the ILDA role: (a) the ILDA must have a certain skill set rather than a specific profession, (b) the ILDA must be educated and demonstrate competence in core knowledge components, (c) the ILDA's primary role is to assess components of informed consent, (d) centers must develop a transparent system to define ILDA independence, (e) the ILDA should have a reporting structure outside the transplant center, (f) the ILDA's role should be integrated throughout the donor care continuum, (g) the ILDA role should include a narrow "veto power." We address controversies in ILDA implementation, and offer pathways to maximize benefits and minimize limitations of approaches that may each meet regulatory requirements but confer different practice benefits. We propose a research agenda to explore the impact of the ILDA.
引用
收藏
页码:518 / 525
页数:8
相关论文
共 26 条
[1]  
Abecassis M, 2000, JAMA-J AM MED ASSOC, V284, P2919
[2]  
[Anonymous], NARRAT INQ BIOETH
[3]  
Brown C., 2014, LIVING DONOR ADVOCAC, P275
[4]  
Chess F., 2014, LIVING DONOR ADVOCAC, P261
[5]  
[Department of Health and Human Services Centers for Medicare & Medicaid Services], 2007, FED REG, V72, P15198
[6]   Guidelines for the psychosocial evaluation of living unrelated kidney donors in the United States [J].
Dew, M. A. ;
Jacobs, C. L. ;
Jowsey, S. G. ;
Hanto, R. ;
Miller, C. ;
Delmonico, F. L. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (05) :1047-1054
[7]  
Gaston RS, 2014, TIMELY TOPICS TRANSP
[8]   Informed Consent for Living Donation: A Review of Key Empirical Studies, Ethical Challenges and Future Research [J].
Gordon, E. J. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (09) :2273-2280
[9]   The Challenge of Informed Consent for Increased Risk Living Donation and Transplantation [J].
Gordon, E. J. ;
Beauvais, N. ;
Theodoropoulos, N. ;
Hanneman, J. ;
McNatt, G. ;
Penrod, D. ;
Jensen, S. ;
Franklin, J. ;
Sherman, L. ;
Ison, M. G. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (12) :2569-2574
[10]  
Hays R., 2014, LIVING DONOR ADVOCAC, P205